Ena Wang, M.D., M.S., has served as Vice President of Cell Therapy and Product Development since June 2021. Prior to joining Nurix, Dr. Wang was Executive Director of Translational Sciences at Allogene Therapeutics and Senior Director of Translational Sciences at AbbVie Corp. Before joining the biopharma industry, Dr. Wang had a distinguished academic career at the National Institutes of Health (NIH), where she served in a variety of roles including Director of the Center for Human Immunology, Director of Molecular Science in the Department of Transfusion Medicine, and Acting Chief of the Infectious Disease and Immunogenetics Section. She has also worked at Sidra Medicine in Qatar, where she served as Chief Research Officer and built state-of-art translational medicine infrastructures and research programs. Dr. Wang has dedicated more than 26-years to translational medicine with a primary focus on cancer immunotherapy and biomarker discovery and has pioneered real-time transcriptional analysis for cancer immune biology and antigen specific T cell monitoring. She has published more than 250 peer-reviewed research articles and is a Co-Founder and Deputy Editor-in-Chief of the Journal of Translational Medicine. Dr. Wang completed her medical degree at Shijiazhuang Medical University and her Master of Medicine degree at the Shanghai Medical College of Fudan University.